Phaseline

Targets › F9

F9 (Coagulation factor IX): drug programs, companies and trials

14 programs from 12 companies in 28 trials: 13 Phase 3, 6 Phase 1, 5 Phase 4, 4 Phase 2; Hematology, Cardiovascular, Neurology; next expected readout Nov 2026.

Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca(2+) ions, phospholipids, and factor VIIIa. (UniProt, P00740)

Open in Phaseline: the race on F9, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
RocheEmicizumab
Coagulation factor IX and X other
F9, F10Phase 4Severe Hemophilia A; Von Willebrand Disease, Type 3; Factor VIII Deficiency, Congenital; Hemophilia A Patient …Nov 2026
CSL BehringProthrombin Complex Concentrate (BE1116)
Coagulation factor VII exogenous protein; Vitamin K-dependent protein S exogenous protein; Vitamin K-dependent protein C exogenous protein
F7, PROS1, PROC, F9, F2Phase 3Complex Cardiovascular Surgery With Cardiopulmonary Bypass; Cardiac Valve Disease; Hemophilia; Liver CirrhosisApr 2027
BiocadANB-002 (arvenacogene sanparvovec)
Adeno-associated viral vector carrying the FIX gene
F9Phase 3Hemophilia BApr 2027
IntraBioTrenonacog Alfa (IB1001)
Coagulation factor IX exogenous protein
F9Phase 3Ataxia-Telangiectasia; CACNA1A; Niemann-Pick Disease, Type CDec 2027
PfizerFidanacogene Elaparvovec (PF-06838435)
Coagulation factor IX exogenous gene
F9Phase 3Hemophilia B; Hemophilia AFeb 2028
CSL BehringEtranacogene Dezaparvovec (CSL222)
Coagulation factor IX exogenous protein
F9Phase 3Hemophilia BOct 2028
BioMarin Pharmaceuticalvaloctocogene roxaparvovec
Coagulation factor IX exogenous protein
F9Phase 3Hemophilia AMar 2029
Icahn School of Medicine at Mount SinaiOral Anticoagulant (OAC) - Vitamin K Antagonist (VKA) or Direct Oral Anticoagula
Vitamin K antagonist or factor Xa/IIa inhibitor anticoagulation
F2, F7, F9, F10Phase 3Atrial Fibrillation–
Shanghai Xinzhi BioMedBBM-H901
Adeno-associated virus (AAV) vector containing human factor IX (hFIX) transgene for gene t
F9Phase 2Hemophilia BJun 2028
Northwell HealthFEIBA
Factor VIII inhibitor bypass activity - prothrombin complex concentrate containing factors
F2, F7, F9, F10Phase 2Cardiac DiseaseNov 2028
Institute of Hematology & Blood Diseases Hospital, ChinaZS801
AAV vector-mediated human factor IX variant gene transfer
F9Phase 1Hemophilia BDec 2028
Baxalta now part of ShireAskBio009 (BAX 335)
Adeno-associated virus serotype 8 (AAV8) delivering Factor IX (FIX) gene therapy
F9Phase 1Hemophilia BJan 2030
Regeneron PharmaceuticalsREGV131-LNP1265
Coagulation Factor IX gene insertion therapy delivered via LNP
F9Phase 1Hemophilia BAug 2034
Institute of Hematology & Blood Diseases Hospital, ChinaBBM-H901
AAV5 vector encoding hyperactive human factor IX mutant (FIX Padua)
F9Phase 1Hemophilia BJun 2035

Conditions

Hemophilia B (10) Hemophilia A (2) Severe Hemophilia A (2) Von Willebrand Disease, Type 3 (2) Factor VIII Deficiency, Congenital (1) Hemophilia A Patient (1) Acquired Hemophilia A (1) Ataxia-Telangiectasia (1) CACNA1A (1) Niemann-Pick Disease, Type C (1) Cardiac Disease (1) Atrial Fibrillation (1)

Modalities

other (6), small molecule (5), protein or peptide (2), mixed (1)

Companies

CSL Behring (2) Institute of Hematology & Blood Diseases Hospital, China (2) BioMarin Pharmaceutical (1) Pfizer (1) Roche (1) Shanghai Xinzhi BioMed (1) IntraBio (1) Baxalta now part of Shire (1) Biocad (1) Northwell Health (1) Icahn School of Medicine at Mount Sinai (1) Regeneron Pharmaceuticals (1)

Related targets

F10 (3) F2 (3) F7 (3) PROS1 (1) PROC (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.